search
Back to results

Type 1 Diabetes Management Using a Very Low Carbohydrate Versus Standard Diet

Primary Purpose

Type1diabetes

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
very low carbohydrate diet
standard carbohydrate diet
Sponsored by
Boston Children's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Type1diabetes focused on measuring very low carbohydrate diet, nutrition, ketogenic diet, ketosis, nutritional ketosis, metabolism, metabolic health

Eligibility Criteria

18 Years - 40 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Males and females with T1D for at least 1 year
  • Age 18 to 40 years
  • Tanner stage ≥ IV
  • BMI 18.5-35 kg/m2
  • Stable glycemic control (HbA1c 6.5-9%)
  • Use of a continuous glucose monitor (CGM)
  • Use of an insulin pump
  • Attendance of at least 1 diabetes care visit over the past 12 months (including virtual)

Exclusion Criteria:

  • Ketoacidosis or severe hypoglycemia with seizure or coma in the past 6 months
  • Dietary restrictions or intolerances that are incompatible with the planned food deliveries, e.g. celiac disease, gastroparesis, certain food allergies
  • Following a weight-loss or otherwise restrictive diet
  • Vigorous exercise >2 hours on >3 days a week
  • History of an eating disorder or at risk for eating disorder, assessed by the Eating Disorders Diagnostic Scale (EDDS)
  • Major medical illness or use of medications other than insulin and metformin that could interfere with metabolic or glycemic variables
  • Significant psychiatric illness
  • Smoking, use of recreational drugs, or excessive alcohol consumption
  • Pregnancy or breastfeeding
  • Anemia
  • For participants who undergo MRI:

    1. Standard MRI exclusion criteria
    2. Irregular menses
    3. Use of psychotropic medication (unless these medications are safe to be held for several days to allow for the acquisition of MRI data)

Sites / Locations

  • Boston Children's HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

very low carbohydrate diet

standard diet

Arm Description

Dietary Intervention, food delivery

Dietary Intervention, food delivery

Outcomes

Primary Outcome Measures

Hemoglobin A1C change
HbA1C change from baseline at 12 weeks will be compared between the 2 interventions

Secondary Outcome Measures

total daily insulin dose
average daily insulin dose over 1 week will be calculated
percent time spent in the glycemic target range of 70-140 mg/dl
will be calculated from 1-week continuous glucose monitoring data
percent time spent below the glycemic target of 70 mg/dl
will be calculated from 1-week continuous glucose monitoring data
percent time in hypoglycemia below 54 mg/dl
will be calculated from 1-week continuous glucose monitoring data
percent time spent above the glycemic target of 140 mg/dl
will be calculated from 1-week continuous glucose monitoring data
percent time spent in hyperglycemia
will be calculated from 1-week continuous glucose monitoring data
blood glucose average
will be calculated from 1-week continuous glucose monitoring data
blood glucose standard deviation
will be calculated from 1-week continuous glucose monitoring data
Glycemic Variability Index, a measure for glycemic variability normalized to mean blood glucose level
will be calculated by dividing blood glucose standard deviation by blood glucose average
Mean Amplitude of Glycemic Excursions (MAGE), a measure for postprandial glycemic variability
will be calculated by dividing blood glucose standard deviation by blood glucose average
fasting total cholesterol
from venous blood
fasting high density lipoprotein cholesterol
from venous blood
fasting low density lipoprotein cholesterol
from venous blood
fasting triglycerides
from venous blood
fasting beta hydroxybutyrate
from venous blood and/or point-of-care testing
fasting high-sensitivity c-reactive protein
from venous blood
Self-reported quality of life assessed per self-report by The Problem Areas in Diabetes Scale (PAID)
The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100.
Becks Depression Inventory II (BDI II) less suicidality
BDI-II less suicidality is a 20-item self-report inventory that measures assesses for presence and severity of depression depressive symptoms. Each item is scored between 0-3. Item scores are added up to a total score (max. 60) and reported.
Yale Food Addiction Scale 2.0 (YFAS 2.0)
Assesses indicators of addictive-like eating.The YFAS includes two scoring options: 1) a "symptom count" that reflects the number of addiction-like criteria endorsed and 2) a dichotomous "diagnosis" that indicates whether a threshold of three or more "symptoms" plus clinically significant impairment or distress has been met. The diagnosis score will be calculated at baseline and used as an effect modifier. Symptom counts will be reported separately as a longitudinal measure.
Highly Processed Food Withdrawal Scale (ProWS)
Assesses withdrawal-type symptoms that may occur when individuals cut down on rewarding foods.

Full Information

First Posted
October 16, 2018
Last Updated
June 29, 2023
Sponsor
Boston Children's Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03710928
Brief Title
Type 1 Diabetes Management Using a Very Low Carbohydrate Versus Standard Diet
Official Title
Type 1 Diabetes Management Using a Very Low Carbohydrate Versus Standard Diet
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 3, 2020 (Actual)
Primary Completion Date
July 31, 2024 (Anticipated)
Study Completion Date
July 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Boston Children's Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Despite major technological advances, management of type one diabetes mellitus (T1D) remains suboptimal, putting millions of people at risk for immediate and long-term complications. After meals, a mismatch between carbohydrate absorption rate and insulin action typically leads to alternating periods of hyper- and hypoglycemia. A conceptually promising approach to control both problems is dietary carbohydrate restriction to reduce postprandial blood glucose changes and insulin needs. In a prior survey study, the investigators documented exceptional glycemic control (HbA1c 5.67%) and low acute complication rates among 316 children and adults with T1D consuming a very-low-carbohydrate diet. To test the feasibility of this approach, the investigators will conduct a randomized-controlled feeding study involving 32 adults and adolescents with T1D. Participants will be randomized to receive a very low carbohydrate vs. standard carbohydrate diet. Participants will be in the study for 12 weeks and receive all their meals by meal delivery.They will share continuous glucose monitoring data with the study team and be in close communication to adjust insulin doses as needed. All participants will have a screening visit, an individual or group education session, and 3 study visits to evaluate diabetes control and metabolic health. Some of these visits will have a fasting blood draw. Two of the visits will also comprise additional metabolic studies to assess glucagon response and brain function during hypoglycemia by magnetic resonance imaging (MRI). Participants will have IV catheters placed and receive IV insulin to drop blood glucose levels to 50 mg/dl for up to 30 minutes. The primary outcome will be HbA1c change from baseline. Secondary outcomes include detailed measures of glycemic variability, metabolic health, and quality of life.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type1diabetes
Keywords
very low carbohydrate diet, nutrition, ketogenic diet, ketosis, nutritional ketosis, metabolism, metabolic health

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
randomized controlled trial, 12-week feeding study
Masking
None (Open Label)
Allocation
Randomized
Enrollment
32 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
very low carbohydrate diet
Arm Type
Experimental
Arm Description
Dietary Intervention, food delivery
Arm Title
standard diet
Arm Type
Active Comparator
Arm Description
Dietary Intervention, food delivery
Intervention Type
Other
Intervention Name(s)
very low carbohydrate diet
Intervention Description
All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement as needed with each meal to support digestive health, and a daily multi-vitamin, magnesium and omega-three supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance. The diet composition will be as follows: 5% carbohydrate, 70% fat, 20% protein.
Intervention Type
Other
Intervention Name(s)
standard carbohydrate diet
Intervention Description
All meals will be delivered and participants will consume study foods exclusively. Participants will receive a daily multi-vitamin and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance. The diet composition will be as follows: 50% carbohydrate, 30% fat, 20% protein.
Primary Outcome Measure Information:
Title
Hemoglobin A1C change
Description
HbA1C change from baseline at 12 weeks will be compared between the 2 interventions
Time Frame
12 weeks - baseline
Secondary Outcome Measure Information:
Title
total daily insulin dose
Description
average daily insulin dose over 1 week will be calculated
Time Frame
week 0 and 12
Title
percent time spent in the glycemic target range of 70-140 mg/dl
Description
will be calculated from 1-week continuous glucose monitoring data
Time Frame
week 0 and 12
Title
percent time spent below the glycemic target of 70 mg/dl
Description
will be calculated from 1-week continuous glucose monitoring data
Time Frame
week 0 and 12
Title
percent time in hypoglycemia below 54 mg/dl
Description
will be calculated from 1-week continuous glucose monitoring data
Time Frame
week 0 and 12
Title
percent time spent above the glycemic target of 140 mg/dl
Description
will be calculated from 1-week continuous glucose monitoring data
Time Frame
week 0 and 12
Title
percent time spent in hyperglycemia
Description
will be calculated from 1-week continuous glucose monitoring data
Time Frame
week 0 and 12
Title
blood glucose average
Description
will be calculated from 1-week continuous glucose monitoring data
Time Frame
week 0 and 12
Title
blood glucose standard deviation
Description
will be calculated from 1-week continuous glucose monitoring data
Time Frame
week 0 and 12
Title
Glycemic Variability Index, a measure for glycemic variability normalized to mean blood glucose level
Description
will be calculated by dividing blood glucose standard deviation by blood glucose average
Time Frame
week 0 and 12
Title
Mean Amplitude of Glycemic Excursions (MAGE), a measure for postprandial glycemic variability
Description
will be calculated by dividing blood glucose standard deviation by blood glucose average
Time Frame
week 0 and 12
Title
fasting total cholesterol
Description
from venous blood
Time Frame
week 0 and 12
Title
fasting high density lipoprotein cholesterol
Description
from venous blood
Time Frame
week 0 and 12
Title
fasting low density lipoprotein cholesterol
Description
from venous blood
Time Frame
week 0 and 12
Title
fasting triglycerides
Description
from venous blood
Time Frame
week 0 and 12
Title
fasting beta hydroxybutyrate
Description
from venous blood and/or point-of-care testing
Time Frame
weeks 0, 1, 2, 4, 6, 9, 12
Title
fasting high-sensitivity c-reactive protein
Description
from venous blood
Time Frame
week 0 and 12
Title
Self-reported quality of life assessed per self-report by The Problem Areas in Diabetes Scale (PAID)
Description
The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100.
Time Frame
week 0, 6, and 12
Title
Becks Depression Inventory II (BDI II) less suicidality
Description
BDI-II less suicidality is a 20-item self-report inventory that measures assesses for presence and severity of depression depressive symptoms. Each item is scored between 0-3. Item scores are added up to a total score (max. 60) and reported.
Time Frame
week 0, 6, and 12
Title
Yale Food Addiction Scale 2.0 (YFAS 2.0)
Description
Assesses indicators of addictive-like eating.The YFAS includes two scoring options: 1) a "symptom count" that reflects the number of addiction-like criteria endorsed and 2) a dichotomous "diagnosis" that indicates whether a threshold of three or more "symptoms" plus clinically significant impairment or distress has been met. The diagnosis score will be calculated at baseline and used as an effect modifier. Symptom counts will be reported separately as a longitudinal measure.
Time Frame
week 0, 6, and 12
Title
Highly Processed Food Withdrawal Scale (ProWS)
Description
Assesses withdrawal-type symptoms that may occur when individuals cut down on rewarding foods.
Time Frame
Baseline, daily on days 1-7, then weekly; primary focus on change from baseline to day 7

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males and females with T1D for at least 1 year Age 18 to 40 years Tanner stage ≥ IV BMI 18.5-35 kg/m2 Stable glycemic control (HbA1c 6.5-9%) Use of a continuous glucose monitor (CGM) Use of an insulin pump Attendance of at least 1 diabetes care visit over the past 12 months (including virtual) Exclusion Criteria: Ketoacidosis or severe hypoglycemia with seizure or coma in the past 6 months Dietary restrictions or intolerances that are incompatible with the planned food deliveries, e.g. celiac disease, gastroparesis, certain food allergies Following a weight-loss or otherwise restrictive diet Vigorous exercise >2 hours on >3 days a week History of an eating disorder or at risk for eating disorder, assessed by the Eating Disorders Diagnostic Scale (EDDS) Major medical illness or use of medications other than insulin and metformin that could interfere with metabolic or glycemic variables Significant psychiatric illness Smoking, use of recreational drugs, or excessive alcohol consumption Pregnancy or breastfeeding Anemia For participants who undergo MRI: Standard MRI exclusion criteria Irregular menses Use of psychotropic medication other than SSRIs or other mild antidepressant or anxiety medications (unless these medications are safe to be held for several days to allow for the acquisition of MRI data)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Belinda Lennerz, MD PhD
Phone
8572183896
Email
belinda.lennerz@childrens.harvard.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Svetlana Azova, MD
Phone
6179196675
Email
svetlana.azova@childrens.harvard.edu
Facility Information:
Facility Name
Boston Children's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Belinda S Lennerz, MD PhD
Phone
857-218-3896
Email
belinda.lennerz@childrens.harvard.edu
First Name & Middle Initial & Last Name & Degree
Svetlana Azova, MD
Phone
6179196675
Email
svetlana.azova@childrens.harvard.edu

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
29735574
Citation
Lennerz BS, Barton A, Bernstein RK, Dikeman RD, Diulus C, Hallberg S, Rhodes ET, Ebbeling CB, Westman EC, Yancy WS Jr, Ludwig DS. Management of Type 1 Diabetes With a Very Low-Carbohydrate Diet. Pediatrics. 2018 Jun;141(6):e20173349. doi: 10.1542/peds.2017-3349. Epub 2018 May 7.
Results Reference
background

Learn more about this trial

Type 1 Diabetes Management Using a Very Low Carbohydrate Versus Standard Diet

We'll reach out to this number within 24 hrs